Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Progress in Medicinal Chemistry -

Progress in Medicinal Chemistry

F.D. King, G. Lawton (Herausgeber)

Buch | Hardcover
232 Seiten
2007
Elsevier Science Ltd (Verlag)
978-0-444-52808-7 (ISBN)
CHF 277,55 inkl. MwSt
What defines a quality lead, where these quality leads come from and how one discovers them has been the subject of intense debate within the pharmaceutical industry. This volume addresses these questions and discusses diabetes, obesity and tuberculosis. It presents research in the field of drug discovery.
The success of any drug discovery project relies upon the quality of the lead that initiates the lead optimization process. What defines a ‘quality lead’, where these ‘quality leads’ come from and how one discovers them has been the subject of intense debate within the pharmaceutical industry, relies upon defining those properties that historically have led to successful drug discovery. This volume addresses these questions and specifically discusses diabetes, obesity and tuberculosis.

Dr Geoff Lawton has extensive experience in new medicine discovery across many therapeutic areas in both large and small companies and is a co-inventor of a marketed drug (Cilazapril). He is a former Director of Chemistry at Roche UK, and Vice-president Chemistry and Preclinical Sciences within Roche Bioscience, Palo Alto, USA. He was for five years the research member of a global therapy area strategy planning team for inflammatory diseases, aligning research with the clinical development and marketing parts of the business.From 2003 to 2007 he was founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portfolio targeting the next generation of ion channel modulating medicines. Since 2001 Geoff has provided scientific and strategic evaluation and advice on drug discovery as an independent consultant for a number small and medium sized biotech companies, CROs, VCs, academic groups and medical research charities. Geoff serves on the Board of Antabio, a French biotech company developing tomorrow’s antibacterial drugs.He is a founder of INMedD, a new medicines discovery social enterprise.

Preface
List of Contributors
Hit and Lead Identification: Efficient practices for drug discovery
DPPIV Inhibition: Promising Therapy for the Treatment of Type 2 Diabetes
Recent Progress Towards Nonpeptide Ligands for the Melanocortin-4 Receptor
Tuberculosis chemotherapy: recent developments and future perspectives
Subject Index
Author Index (Volumes 1-45)
Subject Index (Volumes 1-45)

Reihe/Serie Progress in Medicinal Chemistry
Verlagsort Oxford
Sprache englisch
Maße 140 x 210 mm
Gewicht 420 g
Themenwelt Technik
ISBN-10 0-444-52808-3 / 0444528083
ISBN-13 978-0-444-52808-7 / 9780444528087
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Praxiswissen zu Schimmelpilzschäden in Gebäuden: Mikrobiologie, …

von Irina Kraus-Johnsen

Buch | Hardcover (2024)
Reguvis Fachmedien (Verlag)
CHF 138,60